Molecular Templates Q1 net income $0.6M on revenue $11.1M; MT-6402 shows 2 PRs in HNSCC

Molecular Templates, Inc.

2024-Q1 EPS reported -$0.08

Net income $0.6M ($0.11 basic EPS) vs $10.8M ($2.89) in Q1 2023; revenue $11.1M vs $36.6M.
Cash and equivalents $6.8M; subsequent $9.5M financing closing supports ops into Q4 2024.
MT-6402 monotherapy in HNSCC: 2 confirmed PRs (ongoing 10 & 20 months), 4 SDs in 7 evaluable.
MT-8421 Phase 1 dose escalation ongoing; unique Treg depletion pharmacodynamics.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Molecular Templates, Inc. reported the first quarter of 2024 ended March 31, 2024 results: revenue $11.1 million, net income $0.6 million, EPS $0.11 per basic share and $0.08 per diluted share.

Period: the first quarter of 2024 ended March 31, 2024
Revenue: $11.1 million
Net income: $0.6 million
EPS: $0.11 per basic share and $0.08 per diluted share
Result: reported results

Exact text from the filing

a net income attributable to common shareholders of $10.8 million, or $2.89 per basic and diluted share, for the same period in 2023. Revenues for the first quarter of 2024 were $11.1 million, compared to $36.6 million for the same period in 2023. Total research and development expenses for the first quarter of 2024 were $7.4 million, compared with $19.0 million for

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001171843-24-002920

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.